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Abstract
Background Hyperadrenocorticism is an endocrine disease routinely encountered within primary care practice; 
however, few studies evaluating survival beyond diagnosis have studied this population.
Methods This retrospective cohort study analysed the electronic patient records of 219 cases of 
hyperadrenocorticism from a sample of dogs attending primary care practices in England. Kaplan-Meier plots 
examined the cumulative survival and Cox proportional hazard regression modelling identified factors associated 
with the hazard of all-cause mortality.
Results In the analysis, 179/219 (81.7 per cent) hyperadrenocorticism cases died during the study period with 
a median survival time from first diagnosis of 510 days (95% CI 412 to 618 days). Trilostane was used in 94.1 per 
cent of cases and differentiation between pituitary-dependent and adrenal-dependent disease was made in 20.1 
per cent of cases. In the multivariable analysis, dogs weighing greater than or equal to 15 kg (HR 1.51, 95% CI 
1.06 to 2.15, P=0.023) and those diagnosed greater than or equal to 13 years of age (HR 3.74, 95% CI 2.29 to 
6.09, P<0.001) had increased hazards of all-cause mortality. Dogs that had their initial trilostane dose increased 
had a favourable prognosis (HR 0.49, 95% CI 0.32 to 0.76, P=0.015).
Conclusion This study shows that survival from diagnosis of hyperadrenocorticism appears fair for many dogs 
and provides primary care practitioners with relatable benchmark prognostic figures.
Introduction
Canine hyperadrenocorticism is an endocrine 
disease routinely encountered within primary care 
veterinary practice with an estimated prevalence of 
0.28 per cent.1 The disease is most commonly due to a 
functional pituitary tumour, although in approximately 
15 per cent of cases an adrenal tumour causes the 
excessive circulatory glucocorticoids which ultimately 
produce the classical clinical signs in affected dogs.2 3 
Depending on the duration of the disease, these cases 
show various combinations of polydipsia, polyuria, 
polyphagia, muscle atrophy, hepatomegaly, lethargy 
and dermatological changes.1 4–6 The disease is generally 
associated with older age, with the average age at 
diagnosis within primary care practice of nine years.1 
Alongside their older age, the disease often occurs in 
dogs as one of multiple morbidities including diabetes 
mellitus (in ~10 per cent of hyperadrenocorticism 
cases), calcium oxalate urolithiasis, hypothyroidism, 
pancreatitis and hypertension; however, the causal 
relationships between these diseases are unproven.5 7–10 
The typical treatment for hyperadrenocorticism in UK 
dogs is trilostane (Vetoryl Capsules, Dechra Veterinary 
Products); however, other medical and surgical options 
are available.
A good understanding of the survival characteristics 
of dogs with hyperadrenocorticism attending primary 
care practices is useful for practising veterinary 
surgeons when informing dog owners. These prognostic 
indicators play an important role in presenting options 
for diagnosis as well as treatment, especially given 
the ongoing expense of treatment and the fact that 
the disease typically occurs in an older animal where 
euthanasia may be more frequently considered than 
disease occurring in younger dogs.11 Most of the 
existing survival data have examined dogs undergoing 
treatment for the disease in a referral setting or outside 
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of the UK with studies separating pituitary-dependent 
disease (PDH) and adrenal-dependent disease (ADH). 
Median survival times in dogs with PDH treated with 
trilostane in referral settings have been shown to 
range from 662 to 900 days.5 12 13 This is compared to 
the median survival times of trilostane-treated dogs 
with ADH which are reported between 353 and 475 
days.4 14 A retrospective study in Japan examined the 
survival times of 43 dogs with hyperadrenocorticism 
under primary care and found a statistical difference 
between dogs treated with trilostane and those not 
receiving any treatment.6 Survival times of surgically 
managed hyperadrenocorticism report 72 per cent–79 
per cent survival after 4 years in dogs having undergone 
hypophysectomy for PDH15 16 and 533–953 days median 
survival of ADH cases undergoing adrenalectomy.17 18 
Older age, increased post-adrenocorticotropic hormone 
(ACTH) cortisol concentrations and increased 
bodyweight have all been associated with a poorer 
prognosis for dogs with hyperadrenocorticism.5 13 14
The aim of this study was to examine veterinary 
clinical records to assess the survival characteristics 
of dogs diagnosed with hyperadrenocorticism under 
primary care in England. The hypotheses for this 
study were that age, weight and post-ACTH cortisol 
concentrations are associated with survival. It was 
further hypothesised that trilostane treatment favoured 
survival compared with those that did not receive 
treatment.
Materials and methods
A retrospective cohort design was used to examine the risk 
factors for all-cause mortality in the study population. 
The study used routinely recorded primary care clinical 
data collected within the Veterinary Companion Animal 
Surveillance System project, VetCompass19 and included 
all dogs under veterinary care at collaborating practices 
in England between January 1, 2009 and December 31, 
2013. The end of follow-up for the study was Aprril 4, 
2018. Available clinical data for the study included the 
attending veterinary surgeons’ clinical notes, laboratory 
results and prescribed treatments recorded within the 
anonymised electronic patient records (EPRs). The case 
definition for incident cases of hyperadrenocorticism 
required the dog to have one of the following: i) a 
definitive diagnosis of hyperadrenocorticism recorded 
in the clinical notes; ii) at least one recorded prescription 
of trilostane, with at least one commonly used screening 
test for hyperadrenocorticism recorded (ACTH 
stimulation test, low-dose dexamethasone suppression 
test (LDDST) or urine cortisol-creatinine ratio (UCCR)). 
Cases reported as iatrogenic within the EPR were 
excluded from analysis. The search protocol used to 
find hyperadrenocorticism cases involved searching 
the EPR of all study dogs using key search terms (eg, 
cushin*, hyperadreno*, hac) to identify candidate cases 
with a higher probability of hyperadrenocorticism. 
The full clinical records of a random sample of 52 per 
cent of these candidate cases were manually checked 
to evaluate against the hyperadrenocorticism case 
definition and the study inclusion criteria.
Available demographic data for all study dogs 
included age, sex, neuter status, insurance status, 
breed, maximum recorded bodyweight and clinic ID. 
Continuous variables were assessed for linearity with 
the outcome; where the associations were non-linear, 
the continuous variables were categorised for analysis. 
Age at diagnosis (years) was calculated by using their 
date of birth and date the attending veterinary surgeon 
diagnosed hyperadrenocorticism. This was categorised 
into three groups, based around the median age of the 
study population: less than 10, 10 to less than 13 and 
greater than or equal to 13 (years). Insurance status 
was as recorded in the EPRs as ‘insured’, ‘uninsured’ 
or ‘unknown’ in those with missing information. 
Individual breeds were included in the analysis if there 
were greater than or equal to 12 hyperadrenocorticism 
case dogs of that breed. All other breeds were grouped 
as ‘purebred other’. Maximum recorded bodyweight 
was split into two groups based around the median 
weight of dogs within the study population: those less 
than 15 kg and those greater than or equal to 15 kg. The 
variable of ‘weight compared with breed average’ was 
calculated by comparing the dog’s maximum recorded 
weight with the corresponding breed average.1
Additional risk factors and data were extracted 
manually: date of first diagnosis, date of censorship or 
death, treatment data reported, recorded comorbidities 
and diagnostic ACTH blood results. The date of first 
diagnosis and inclusion into the study was defined as 
either the first date for a recorded final diagnosis or 
the first date that trilostane was prescribed for cases 
without a formally recorded diagnostic term in the 
clinical notes. The end date was recorded as the date of 
death or date of the last clinical record during the study 
period in those that were censored (those still alive at the 
end of the study period or lost to follow-up). Trilostane 
dose (mg/kg/day) was recorded from the clinical notes 
or manually calculated using the prescribed amount 
(mg) given to the dogs and the nearest recorded weight 
(kg) to the date of treatment. Trilostane dose was 
calculated each time a change to the dose was made 
by the attending veterinarian permitting calculation 
of the dogs’ mean lifetime trilostane dose weighted 
by the length of time spent on each dose ((dose 1×x 
days+dose 2×y days+….)/total number of days). A 
binary variable grouped those with a mean lifetime 
trilostane dose less than or equal to 3 mg/kg/day and 
those greater than 3 mg/kg/day. This cut off was based 
on the recommended starting doses for trilostane in 
dogs during the study period.20 Further information on 
trilostane was extracted including frequency of dose 
administration and whether changes were made to the 
initial dose (increased, decreased, stopped or no change 
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made). A comorbidity was recorded if the dog had 
another chronic disease, as diagnosed in the EPR (either 
before or subsequently hyperadrenocorticism) or there 
was evidence of treatment or management of a chronic 
disease concurrently with hyperadrenocorticism.21 
This included chronic heart disease, diabetes mellitus, 
hypertension, hypothyroidism, chronic kidney disease, 
chronic hepatitis, chronic skin disease (atopy or chronic 
pyoderma), urolithiasis, malignant neoplastic disease 
and osteoarthritis. Concurrent diabetes mellitus and 
hypertension were analysed as separate risk factors.10 22 
Hypertension was defined as those with a conscious 
systolic arterial blood pressure measurement recorded 
at greater than 150 mmHg or a diagnosis recorded in the 
free text.23 Dogs with neurological signs were defined as 
those with one or more of the following: seizures with 
no attributed alternative diagnosis, behaviour change, 
signs of cognitive dysfunction or apparent blindness.24 25
Data were cleaned in Microsoft Excel (Microsoft, 
Redmond, Washington, USA) before being uploaded 
into Stata V.15 (StataCorp, College Station, Texas, USA) 
for statistical analysis. Categorical data were presented 
showing the count and corresponding percentage. 
Quantitative data were assessed graphically for 
normality with normally distributed data summarised 
using the mean (sd) and non-normally distributed data 
using the median (IQR and range). Chi-squared analysis 
compared the association between two categorical risk 
factors. A Kaplan-Meier plot described the all-cause 
mortality trend of the case dogs and survival differences 
were explored using the log-rank test. Median survival 
time was defined as the point at which the cumulative 
percentage of dogs surviving from the date of 
hyperadrenocorticism diagnosis reached 50 per cent.26 
Univariable and multivariable Cox proportional hazard 
modelling were used to assess associations between 
the recorded risk factors and hazard of death (all-cause 
mortality). Risk factors in the univariable analysis with 
a likelihood ratio test (LRT) of P<0.2 for the outcome of 
dying were carried forward for multivariable modelling. 
A forwards stepwise manual approach was used to build 
the multivariable model with risk factors kept in the 
final model after assessing for effects of confounding 
and if they were associated with the outcome of dying 
(LRT P<0.05). The proportional hazards assumption 
that the HRs are constant over time was assessed by 
visual inspection of log-minus-log survival plots and 
by statistical assessment of Schoenfeld residuals.27 The 
clinic ID was assessed as a frailty term to account for the 
correlated nature of the data across different veterinary 
practices with the LRT of theta used to assess if within-
patient correlation affected the model. Age was assessed 
for linearity using the LRT for extralinear effect and 
goodness of fit of the final model was evaluated using 
visual inspection of Cox-Snell residuals.26 Confounding 
factors were assessed by substantial variation in HRs 
with inclusion of an additional risk factor. Plausible 
pairwise interactions were examined with the LRT of 
homogeneity. Dogs with missing data for the risk factors 
of interest were excluded from the multivariable Cox 
proportional hazards models. Missing data were also 
excluded from the univariable analysis if the missing 
category was the sole reason for a significant risk factor 
variable (P<0.2).
Sample size calculations using Stata V.15 estimated 
that for a Cox proportional hazards analysis 208 dogs 
would be required to observe an HR of 2 at 5 per cent 
significance, 80 per cent power, with an expected 
proportion of deaths at 80 per cent and 15 per cent lost 
to follow-up.
Results
Descriptive statistics
The study included 193,814 dogs attending 110 
primary care veterinary practices in England between 
January 1, 2009 and December 31, 2013. Of the 2502 
dogs identified as candidate hyperadrenocorticism 
cases from the search terms, 1178 (52.0 per cent) were 
manually reviewed in detail against the case definition. 
From these candidate cases 219 dogs were included in 
the analysis. There were 179 (81.7 per cent) cases that 
died within the study period with 136 (76.0 per cent) of 
these recorded to be via euthanasia. The remaining 34 
(15.5 per cent) dogs were censored and 6 were still alive 
at the end of the study observation. Median follow-up 
time for cases was 424 days (IQR 119–779 days, range 
1–2192 days).
The maximum recorded bodyweight (kg) of the cases 
was heavily right skewed with a median of 12.75 kg (IQR 
9.20–21.00, range 2.48–65.90). The age at diagnosis 
(years) was normally distributed with a mean age of 
10.99 years (sd 2.49) and a range of 4.46–18.00 years. 
The cases included 104 females and 115 males of which 
86 (82.7 per cent) and 83 (72.2 per cent) were recorded 
as neutered, respectively. The most represented breed-
types were crossbreeds (n=47, 21.5 per cent), Jack 
Russell terriers (21, 9.6 per cent), Yorkshire terriers 
(16, 7.3 per cent), Bichon Frise (13, 5.9 per cent), 
Staffordshire bull terriers (13, 5.9 per cent) and West 
Highland white terriers (12, 5.5 per cent). Insurance 
status was unrecorded in 41 dogs with 126 (57.5 per 
cent) known to be insured. The proportion insured 
increased to 70.2 per cent in those weighing greater 
than or equal to 15 kg (chi-squared test, P=0.01). 
Overall, 206 (94.1 per cent) of the cases received 
trilostane at some point within their clinical history, 1 
dog (0.5 per cent) had surgical treatment via unilateral 
adrenalectomy and the remaining 12 dogs never 
received any treatment. Of the dogs initially treated with 
trilostane, 32 (15.5 per cent) later had their treatment 
ceased. The starting dose of trilostane was available for 
199 (96.6 per cent) cases and was normally distributed 
around the manufacturer’s recommended starting 
doses with a mean of 3.30 mg/kg/day (sd 1.28).20 The 
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Figure 1 Kaplan-Meier survival curve of all-cause mortality in dogs diagnosed with hyperadrenocorticism at UK primary care practices. Survival time represents the 
time from when the disease was initially detected until the time of death due to all-cause mortality.
mean lifetime trilostane dose was skewed to the right 
with a median dose of 3.09 mg/kg/day (IQR 2.45–4.50). 
Frequency of dosing was available for 194 (94.2 per 
cent) cases with 178 (91.8 per cent) receiving once-daily 
dosing of trilostane for the duration of their treatment. 
Of the 100 (48.5 per cent) cases with blood test results 
recorded at each monitoring ACTH stimulation test, 32 
dogs never had a post-ACTH cortisol drop below the 
upper reference range of 250 nmol/l and 21 had results 
fall below the lower reference range 40 nmol/l at least 
once.28 29 There were 28 dogs with suspected iatrogenic 
hypoadrenocorticism or adverse response to trilostane 
at some point in their EPR that were managed by either 
reducing the trilostane dose or stopping treatment. 
The most commonly used diagnostic screening tests 
reported to have been used were the ACTH stimulation 
test (n=206, 94.1 per cent), LDDST (70, 32.0 per cent) 
and UCCR (58, 26.5 per cent). All dogs had at least an 
ACTH stimulation test or an LDDST recorded before 
diagnosis. Hyperadrenocorticism was differentiated in 
44 (20.1 per cent) cases: 30 (68.2 per cent) had PDH 
and 14 (31.8 per cent) had ADH. Differentiation was 
based on reported interpretation of ultrasonographic 
imaging of the adrenals and interpretation of an LDDST. 
At least one comorbidity to hyperadrenocorticism was 
recorded in 141 cases (68.5 per cent). Of these, 61.0 
per cent had one other comorbidity and a maximum of 
five comorbidities. Forty-five cases (11.5 per cent) were 
recorded with central neurological signs, 22 (10.1 per 
cent) dogs concurrently had diabetes mellitus and 6 
(2.7 per cent) had concurrent hypothyroidism.
Survival analysis
The overall median survival time following diagnosis 
with hyperadrenocorticism (n=219) was 510 days 
(95% CI 412 to 618 days) (figure 1). Median survival time 
for cases treated with trilostane (n=206) was 521 days 
(95% CI 416 to 634 days) and did not differ statistically 
from the 18 cases not treated with trilostane (178 days, 
95% CI 3 to 1015 days, P=0.590). Median survival time 
for cases that had trilostane treatment ceased or were 
untreated was 484 days (95% CI 373 to 689) compared 
with 517 days in those continuously kept on treatment 
(95% CI 376 to 637 days, P=0.688). Of the dogs where 
disease differentiation was recorded by the attending 
veterinary surgeon, the median survival time of those 
with ADH was 596 days (n=14, 95% CI 166 to 941) and 
did not differ statistically from the 30 dogs diagnosed 
with PDH (700 days, 95% CI 305 to 1125, P=0.31). The 
cumulative proportion of all cases surviving to one year 
was 0.60 (95% CI 0.53 to 0.66) with 0.35 (95% CI 0.28 
to 0.41) surviving to two years.
Univariable Cox proportional hazards analysis 
identified loose association (P<0.2) of the following risk 
factors that were taken forward to the final multivariable 
model: bodyweight, age, insurance status, neurological 
signs, changes in trilostane dosage and diagnostic 
pre-ACTH and post-ACTH cortisol levels (table  1). 
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Table 1 Univariable Cox proportional hazards regression analysis for risk factor association with death (all-cause mortality) in dogs diagnosed with 
hyperadrenocorticism at primary care veterinary practices in England (n=219)
Variable Frequency (%)
Median survival 
time (days) 95% CI HR 95% CI
Category P 
value*
Variable P 
value†
Weight (kg) 0.002
  <15 135 (61.6) 634 424 to 726 Baseline - -
  ≥15 84 (38.4) 427 296 to 530 1.61 1.19 to 2.18 0.002
Age at diagnosis (years)
  <10 74 (33.8) 718 593 to 896 Baseline - - <0.001
  10 to <13 96 (43.8) 458 319 to 637 1.48 1.04 to 2.12 0.029
  ≥13 49 (22.4) 239 144 to 449 2.94 1.93 to 4.48 <0.001
Sex neuter
  Female entire 18 (8.2) 427 178 to 1223 1.04 0.56 to 1.92 0.911 0.899
  Female neutered 86 (39.3) 442 355 to 637 Baseline - -
  Male entire 32 (14.6) 535 159 to 714 1.13 0.73 to 1.76 0.578
  Male neutered 83 (37.9) 546 376 to 718 0.95 0.68 to 1.33 0.780
Sex
  Female 104 (47.5) 440 355 to 637 Baseline - - 0.970
  Male 115 (52.5) 535 376 to 683 0.99 0.74 to 1.34 0.970
Neuter status
  Entire 50 (22.8) 535 220 to 714 Baseline - -
  Neutered 169 (77.2) 510 412 to 618 1.13 0.79 to 1.61 0.501 0.506
Insured
  Yes 126 (57.5) 517 412 to 642 0.74 0.52 to 1.07 0.113 0.059
  No 52 (23.7) 332 219 to 535 Baseline - -
  Unrecorded 41 (18.8) 717 442 to 896 0.55 0.34 to 0.91 0.018
Breed
  Crossbred 47 (21.5) 432 221 to 726 Baseline - - 0.286
  Bichon Frise 13 (5.9) 540 119 to 1259 0.72 0.36 to 1.45 0.361
  Jack Russell terrier 21 (9.6) 807 484 to 1445 0.57 0.31 to 1.04 0.065
  Staffordshire bull terrier 13 (5.9) 700 215 to 941 1.01 0.54 to 1.89 0.977
  West Highland white terrier 12 (5.5) 396 72 to 1022 0.93 0.46 to 1.85 0.832
  Yorkshire terrier 16 (7.3) 642 239 to 1015 0.80 0.43 to 1.50 0.487
  Other purebreds 97 (44.3) 440 311 to 568 1.10 0.75 to 1.62 0.618
Purebred status
  Purebred 172 (78.5) 532 424 to 637 Baseline - - 0.637
  Crossbred 47 (21.5) 432 221 to 726 1.09 0.77 to 1.55 0.635
Weight to breed
  Average 81 (37.0) 479 332 to 681 Baseline - - 0.900
  Above 73 (33.3) 596 441 to 717 0.93 0.65 to 1.33 0.705
  Below 20 (9.1) 373 199 to 739 1.09 0.61 to 1.95 0.769
  Crossbreed 45 (20.6) 389 217 to 726 1.07 0.72 to 1.60 0.728
Treated with trilostane
  Yes 206 (94.1) 521 416 to 634 Baseline - - 0.600
  No 13 (5.9) 178 3 to 1015 1.20 0.61 to 2.36 0.590
Trilostane dose frequency
  Once daily 178 (81.3) 532 424 to 634 Baseline - - 0.372
  Twice daily 16 (7.3) 833 311 to 1109 0.71 0.41 to 1.23 0.226
  Not given 13 (5.9) 178 3 to 1015 1.20 0.61 to 2.36 0.584
  Unknown 12 (5.5)
Mean lifetime trilostane dose (mg/kg)
  Not given 13 (5.9) 178 3 to 1015
  ≤3 68 (31.1) 449 308 to 605 1.16 0.78 to 1.74 0.462 0.463
  >3 131 (59.8) 596 427 to 718 Baseline - -
  Missing 7 (3.2)
Comorbidities
Neurological signs
  Yes 45 (20.6) 479 300 to 596 1.44 1.01 to 2.03 0.042 0.048
  No 174 (79.5) 535 389 to 689 Baseline - -
Hypertensive
  Yes 27 (12.3) 660 429 to 779 Baseline - - 0.881
  No 15 (6.9) 479 178 to 753 0.93 0.46 to 1.84 0.826
  Not checked 177 (80.8) 479 357 to 605 0.87 0.48 to 1.58 0.650
Continued
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Variable Frequency (%)
Median survival 
time (days) 95% CI HR 95% CI
Category P 
value*
Variable P 
value†
Diabetes mellitus
  Yes 22 (10.1) 479 119 to 1102 0.91 0.57 to 1.46 0.698 0.695
  No 197 (89.9) 510 412 to 605 Baseline - -
No. of comorbidities
  0 78 (35.6) 334 225 to 432 Baseline - -
  ≥1 141 (64.4) 568 479 to 715 1.23 0.89 to 1.70 0.198 0.210
Changes to trilostane
  Increased 55 (25.1) 733 532 to 941 0.50 0.34 to 0.73 <0.001 0.002
  Decreased 23 (10.5) 681 308 to 830 0.56 0.34 to 0.93 0.023
  No change 94 (42.9) 332 221 to 432 Baseline - -
  Stopped 34 (15.6) 546 412 to 717 0.73 0.48 to 1.10 0.133
  Not given 13 (5.9)
Pre-ACTH cortisol (nmol/l)
  Unknown 154 (70.3) 449 355 to 605 1.44 0.95 to 2.19 0.089 0.154
  <150 34 (15.5) 577 340 to 942 Baseline - -
  ≥150 31 (14.2) 521 84 to 831 1.58 0.93 to 2.70 0.092
Post-ACTH cortisol (nmol/l)
  Unknown 142 (64.8) 449 334 to 618 1.48 0.98 to 2.23 0.062 0.091
  <800 36 (16.5) 779 577 to 1041 Baseline - -
  ≥800 41 (18.7) 432 269 to 535 1.64 1.00 to 2.68 0.049
*Wald P value.
†LRT P value.
ACTH, adrenocorticotropic hormone; LRT, likelihood ratio test.
Table 1 Continued
Table 2 Multivariable Cox proportional hazards regression results for risk 
factors associated with death (all-cause mortality) among dogs diagnosed 
with hyperadrenocorticism at primary care veterinary practices in England 
(n=206)
Variable HR 95% CI Variable P value*
Bodyweight (kg)
  <15 Baseline - 0.023
  ≥15 1.51 1.06 to 2.15
Age at diagnosis (years)
  <10 Baseline - <0.001
  10 to <13 1.70 1.14 to 2.54
  ≥13 3.74 2.29 to 6.09
Changes to trilostane
  No change Baseline - 0.015
  Increased 0.49 0.32 to 0.76
  Decreased 0.78 0.44 to 1.38
  Stopped 0.72 0.44 to 1.16
Clinic ID LRT of theta=0.023
*LRT P value.
LRT, likelihood ratio test.
Univariable analysis did not identify associations with 
any breeds. The origin of the disease and whether or not 
dogs were treated with trilostane also did not show an 
association with all-cause mortality in the univariable 
analysis.
The final multivariable Cox proportional hazards 
model included three risk factors as well as the clinic 
ID, included as a frailty term (table 2). Dogs greater than 
or equal to 15 kg had 1.51 the hazard of dying from 
all-cause mortality compared with those less than 15 kg 
(95% CI 1.06 to 2.15, P=0.023). Cases greater than or 
equal to 13 years of age had 3.74 the hazards of death 
compared with those less than 10 years (95% CI 2.29 
to 6.09, P<0.001). Age was not included as a linear 
term as this did not improve model fit. Cases that had 
their starting dose increased had 0.49 the hazards of 
all-cause mortality compared with those where no dose 
change was made (95% CI 0.32 to 0.76, P=0.015). No 
confounding risk factors or interactions were found. 
Visual interpretation of Cox-Snell residuals showed 
good model fit and there was no evidence of violation of 
the proportional hazards assumption.
Discussion
This study identified a median survival time for 
diagnosed cases of hyperadrenocorticism within 
primary care practice in England as 510 days (95% CI 
412 to 618 days). This estimate lies comfortably 
within previous survival time estimates ranging from 
353 to 900 days.4–6 12–14 No statistically significant 
difference in the median survival times of those with 
ADH (596 days, 95% CI 166 to 941, n=14) and PDH 
was found (700 days, 95% CI 305 to 1125, P=0.310, 
n=30). The final multivariable model identified 
older age at diagnosis, a greater maximum recorded 
bodyweight and no alteration to the starting trilostane 
dose as risk factors for increased hazard of death from 
all-cause mortality. This concurs with previous studies 
investigating the survival characteristics of dogs with 
hyperadrenocorticism.5 6 13 14 The increased hazard 
with increasing age is unsurprising, with older dogs 
having a naturally shorter expected onward survival 
to younger dogs. Dogs weighing greater than or equal 
to 15 kg had one and a half times the hazard of death 
from all-cause mortality compared with those less 
than 15 kg in weight. The variable investigating those 
with a bodyweight greater than the breed average was 
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not significant in the univariable analysis therefore 
this could suggest a breed difference in survival rather 
than dogs that are overweight. This could be due to a 
shorter life expectancy in larger breed dogs30 or that 
larger breed dogs are thought to be at increased risk of 
ADH, which in itself has been associated with poorer 
survival times.31 The variable looking at changes made 
to the initial trilostane dose interestingly found that 
the cases with the initial trilostane dose increased 
were at reduced risk of dying compared with those 
with no change made to the initial trilostane dose. The 
association with this needs to be interpreted cautiously. 
This effect could be due to reverse causality; cases that 
live longer may be more likely to have a dose change. It 
could be that dogs with longer survival may have had 
more frequent veterinary care with more attention paid 
to optimise the dosage (either increased, decreased or 
stopped). Also measurement error of the diagnostic 
screening tests will have resulted in a number of 
misclassifications therefore dogs having their trilostane 
stopped could have been initially incorrectly diagnosed 
with hyperadrenocorticism. As a higher mean lifetime 
trilostane dose was not significant in the model, it 
does not seem that higher doses of trilostane favour 
survival. The presence of at least one comorbidity did 
not increase the risk of all-cause mortality in this study. 
It could have been assumed that the additional burden 
of a comorbidity may worsen quality of life and add 
financial pressure therefore influencing euthanasia 
decisions. The presence of neurological signs was 
suggestive of increased risk of dying in the univariable 
results but was not significant after accounting for 
age in the final model and comorbidity with diabetes 
mellitus was not associated with reduced survival in 
this study which contradicts the findings of another 
study.8 The proportion of hyperadrenocorticism dogs 
with concurrent diabetes mellitus has previously been 
reported at about 10 per cent–14 per cent5 8 which 
is consistent with this study, finding 10 per cent of 
hyperadrenocorticism cases concurrently had diabetes 
mellitus.
In this analysis, only 44 (21.1 per cent) cases were 
differentiated into their origin of hyperadrenocorticism 
with the option to differentiate often suggested by the 
attending veterinary surgeon but rarely taken up by 
owners, even though this is deemed an important 
step in the diagnosis process by the American College 
of Veterinary Internal Medicine(ACVIM) consensus 
guidelines.32 Those cases differentiated were based 
on interpretation of ultrasonographic imaging of the 
adrenals or through interpretation of the LDDST with 
no other methods of differentiation recorded. With 
the attending veterinarian not always confident in 
their differentiation and potential measurement error, 
there is a possibility of misclassification bias of those 
where an origin of hyperadrenocorticism is recorded. 
The reason for low uptake of differentiation could 
be financial, no plans to treat surgically or it was not 
strongly recommended by the veterinary surgeon. Due 
to the low numbers of those tentatively differentiated, 
it was not possible to precisely compare the survival 
of the two main forms of hyperadrenocorticism in the 
current study, resulting in low statistical power and 
wide CIs around the survival estimates. The underlying 
aetiologies of the two causes of hyperadrenocorticism 
and their treatment recommendations are quite 
different yet the overall clinical signs are similar due to 
the resulting excessive glucocorticoid. They are often 
grouped together as one disease however in a study 
such as this, the measure of effect may well be diluted 
using this approach of a single disease diagnosis.
Median survival for cases treated with trilostane 
(n=206) was 521 days (95% CI 416 to 634 days) 
and did not statistically differ from the 18 cases not 
treated with trilostane (178 days, 95% CI 3 to 1015 
days, P=0.590). Due to the low numbers of those 
untreated resulting in wide CIs and the retrospective 
design of this observational study, it is not feasible 
to draw inferences from the comparison of the two 
treatment groups. A retrospective study in Japan found 
a significant difference in survival times in those treated 
with trilostane and those untreated. Interestingly, 
due to cultural preferences, euthanasia was rarely 
conducted in Japan reducing some bias that can easily 
be introduced into observational veterinary studies.6 33 
A future study could be warranted to further investigate 
the benefits of trilostane treatment.
VetCompass data used in this study are 
generalisable to veterinary practices in England, with 
participating practices located across the country 
using opt-out owner consent.19 There are limitations 
to this study. The data analysed were not primarily 
recorded for research purposes. Cases were included if 
a diagnosis of hyperadrenocorticism was recorded in 
the EPR, however no independent confirmation of the 
diagnosis was possible due to the retrospective nature 
of the data. Additionally, measurement error from the 
diagnostic screening tests used could have introduced 
bias into this study. The recommended gold standard 
diagnostic screening test is the LDDST, which was 
recorded in only 32.0 per cent of the dogs included.32 
The ACTH stimulation was the predominant diagnostic 
test used in this study population which, with a low 
sensitivity (ie, the proportion of all true cases that are 
detected), increases the potential for missed cases 
in primary care practice and consequently in this 
study.31 32 34–36 The poor specificity of the UCCR could 
contribute to misclassification of cases, however this 
test was always used for diagnosis in combination 
with an ACTH stimulation or an LDDST for dogs 
in this study. Therefore, it does not appear that a 
diagnosis of hyperadrenocorticism was made solely 
using a UCCR in any of these cases. The outcome of 
interest was all-cause mortality with the definitive 
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cause of death rarely recorded therefore it was not 
possible to attribute whether these deaths were as a 
result of hyperadrenocorticism. The date of diagnosis 
recorded in the EPR was used as the starting point for 
survival estimation, which will differ from the date 
these cases first developed hyperadrenocorticism. 
Gaining the definitive diagnosis depends on factors 
such as the severity of the dog’s clinical signs 
to warrant the initial veterinary consultation or 
development of concurrent disease associated with 
hyperadrenocorticism, which raise the clinician’s 
suspicion of the disease.37 These factors will vary 
among dogs and likely underestimate the median 
survival estimate. There is potential for selection bias 
in this study. Over 95 per cent of dogs in the current 
study were treated with trilostane at some point, which 
reflects the management of hyperadrenocorticism 
within primary care veterinary practice. Confirming 
a diagnosis of hyperadrenocorticism requires uptake 
of diagnostic tests and an initial financial outlay by 
an owner. It is likely that most decisions to diagnose 
and later differentiate were made by the owner and 
attending veterinary surgeon before investigation. 
Therefore, there will be dogs seen at participating 
veterinary practices with hyperadrenocorticism that 
were left undiagnosed and hence not included in 
this study.37 Another study is warranted to compare 
the characteristics of dogs suspected of disease and 
those with a confirmed diagnosis to better understand 
the reason for not obtaining a definitive diagnosis. In 
this analysis, 57 per cent of dogs were insured which 
is a higher proportion than expected.30 This again 
corresponds with the above argument that the case 
definition is more likely to have selected for dogs whose 
owners wish to and were able to investigate and treat. 
Finally, an assumption of survival analyses is that the 
survival pattern of those with complete follow up are 
the same as those censored; however, in a retrospective 
study this assumption cannot be assessed. Those lost 
to follow-up by moving practice or the practice can no 
longer contact may differ from the treated group.
In summary, this study has highlighted the 
practicalities of hyperadrenocorticism management 
within primary care practice in England with disease 
origin infrequently differentiated and trilostane the 
predominate treatment for the disease. Survival 
times following diagnosis were generally fair and are 
consistent with other studies, with prognosis found to 
be less favourable in dogs of greater bodyweight, those 
diagnosed at an older age and those where no changes 
to the starting trilostane dose were made.
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